Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation - PubMed (original) (raw)
. 1994 May 1;83(9):2619-26.
Affiliations
- PMID: 7513208
Free article
Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation
T Tsujimura et al. Blood. 1994.
Free article
Abstract
The c-kit proto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in hematopoiesis, especially in mast cell growth and differentiation. Although a number of dominant loss-of-function mutations of c-kit gene have been well characterized in mice, rats, and humans, little is known about the c-kit mutations contributing to ligand-independent activation of the c-kit receptor tyrosine kinase (KIT). In a murine mastocytoma cell line, P-815, KIT has been found to be constitutively phosphorylated on tyrosine and activated in a ligand-independent manner. Sequencing of the whole coding region of c-kit cDNA showed that c-kit cDNA of P-815 cells carries a point mutation in codon 814, resulting in amino acid substitution of Tyr for Asp. Murine wild-type c-kit cDNA and mutant-type c-kit cDNA encoding Tyr in codon 814 were expressed in cells of a human embryonic kidney cell line, 293T. In the transfected cells, mutant-form KITTyr814 was strikingly phosphorylated on tyrosine and activated in immune complex kinase reaction regardless of stimulation with a ligand for KIT (stem cell factor), whereas tyrosine phosphorylation and activation was barely detectable in wild-form KIT. The data presented here provide evidence for a novel activating mutation of c-kit gene that might be involved in neoplastic growth or oncogenesis of some cell types, including mast cells.
Similar articles
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, et al. Furitsu T, et al. J Clin Invest. 1993 Oct;92(4):1736-44. doi: 10.1172/JCI116761. J Clin Invest. 1993. PMID: 7691885 Free PMC article. - Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3.
Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y. Tsujimura T, et al. Int Arch Allergy Immunol. 1995 Apr;106(4):377-85. doi: 10.1159/000236870. Int Arch Allergy Immunol. 1995. PMID: 7536501 - Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.
Kanakura Y, Furitsu T, Tsujimura T, Butterfield JH, Ashman LK, Ikeda H, Kitayama H, Kanayama Y, Matsuzawa Y, Kitamura Y. Kanakura Y, et al. Leukemia. 1994 Apr;8 Suppl 1:S18-22. Leukemia. 1994. PMID: 7512180 - Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor.
Kitamura Y, Tsujimura T, Jippo T, Kasugai T, Kanakura Y. Kitamura Y, et al. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):54-6. doi: 10.1159/000236929. Int Arch Allergy Immunol. 1995. PMID: 7542102 Review. - Steel factor and c-kit protooncogene: genetic lessons in signal transduction.
Lev S, Blechman JM, Givol D, Yarden Y. Lev S, et al. Crit Rev Oncog. 1994;5(2-3):141-68. doi: 10.1615/critrevoncog.v5.i2-3.30. Crit Rev Oncog. 1994. PMID: 7531500 Review.
Cited by
- 4-(Imidazo[1,2-a]pyridin-3-yl): pyrimidine derivatives as anticancer agents.
Al-Horani RA. Al-Horani RA. Pharm Pat Anal. 2023 Jan;12(1):13-18. doi: 10.4155/ppa-2022-0033. Epub 2022 Nov 10. Pharm Pat Anal. 2023. PMID: 36354042 Free PMC article. - Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells.
Paez PA, Kolawole M, Taruselli MT, Ajith S, Dailey JM, Kee SA, Haque TT, Barnstein BO, McLeod JJA, Caslin HL, Kiwanuka KN, Fukuoka Y, Le QT, Schwartz LB, Straus DB, Gewirtz DA, Martin RK, Ryan JJ. Paez PA, et al. J Pharmacol Exp Ther. 2020 Jul;374(1):104-112. doi: 10.1124/jpet.119.264234. Epub 2020 May 20. J Pharmacol Exp Ther. 2020. PMID: 32434944 Free PMC article. - Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment.
Tamlin VS, Bottema CDK, Peaston AE. Tamlin VS, et al. Vet Med Sci. 2020 Feb;6(1):3-18. doi: 10.1002/vms3.201. Epub 2019 Oct 24. Vet Med Sci. 2020. PMID: 31650704 Free PMC article. Review. - M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells.
Hara Y, Obata Y, Horikawa K, Tasaki Y, Suzuki K, Murata T, Shiina I, Abe R. Hara Y, et al. PLoS One. 2017 Apr 12;12(4):e0175514. doi: 10.1371/journal.pone.0175514. eCollection 2017. PLoS One. 2017. PMID: 28403213 Free PMC article. - Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis.
Kim DK, Beaven MA, Kulinski JM, Desai A, Bandara G, Bai Y, Prussin C, Schwartz LB, Komarow H, Metcalfe DD, Olivera A. Kim DK, et al. PLoS One. 2016 Sep 9;11(9):e0162831. doi: 10.1371/journal.pone.0162831. eCollection 2016. PLoS One. 2016. PMID: 27611333 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials